Research Links Prenatal Paracetamol Exposure to Changes in Ovarian Development

Researchers in Denmark have identified a potentially surprising link between prenatal exposure to paracetamol (commonly known as Tylenol) and variations in markers of ovarian development in girls tracked from infancy through adolescence. The study, published in Human Reproduction Open, suggests that fetal exposure to the drug may have lasting effects on female reproductive health, although the findings do not conclusively prove causation.

Study Details

Led by Dr. Margit Bistrup Fischer, a post-doctoral researcher in the Department of Growth and Reproduction at Rigshospitalet in Copenhagen, the study followed 302 girls from a prospective Danish pregnancy cohort. Researchers utilized detailed questionnaires and urine samples to identify instances of paracetamol use during pregnancy. Their analysis unveiled trends in ovarian development markers, such as reduced ovarian and uterine volumes among girls exposed to the medication.

The study indicated that prenatal exposure during early pregnancy was associated with a reduced ovarian volume and smaller uterine volume, while later exposure correlated with fewer ovarian follicles. Some girls exposed early in pregnancy exhibited lower anti-Müllerian hormone (AMH) levels—a marker often used in adults to determine ovarian reserve, though the implications for infants remain unknown. To verify these findings, researchers observed a separate cohort of 1,210 girls through adolescence, revealing similar patterns.

Broader Context and Implications

Previous research on rodents suggested fetal exposure to paracetamol might impact ovarian follicle reserves and reproductive lifespan, prompting a deeper investigation into potential human effects. The widespread use of paracetamol during pregnancy, exceeding half of pregnant women globally, accentuates the need for further scrutiny.

Despite the findings, both Dr. Fischer and other medical professionals, such as Dr. Lucy Hooper, emphasize caution in interpretation. Hooper noted the small subgroup size and potential measurement imprecision, advocating for continued adherence to current medical guidelines, recommending minimal effective paracetamol dosages.

Dr. Fischer indicated that the study might not immediately alter medical advice but could encourage more careful deliberation regarding medication use. Further large-scale studies with extended follow-up durations are necessary to clarify the connection to reproductive outcomes.

Ultimately, healthcare decisions regarding paracetamol use during pregnancy should rely on individual symptoms and involve consultation with medical professionals. Alternative approaches, like rest and hydration, could suffice in some situations.